Concert Pharmaceuticals Announces Data Presentations at Neuroscience 2011
Demonstrates Potential of Deuterium-Containing GABAA Modulators
LEXINGTON, Mass.--(BUSINESS WIRE)--Oct 19, 2011 - Concert Pharmaceuticals, Inc. today announced that two abstracts related to the company's deuterium-containing GABAA modulators have been accepted for poster presentations at The Society for Neuroscience Annual Meeting, Neuroscience 2011, being held November 12-16, 2011 in Washington, DC. Full abstracts can be viewed online at http://www.sfn.org/am2011/.
The schedule and details for Concert's poster presentations at Neuroscience 2011 are as follows:
- “C-21191: Deuterated
subtype-selective GABAA modulator for spasticity and
Program # 338.05 / Poster #: C42; Location: Hall A-C; Presentation time: Monday, November 14, 2011, 8:00am - 9:00am ET.
- “Deuterated subtype-selective
GABAA modulators for cognition enhancement,”
Program # 338.06 /
Poster #: C43; Location: Hall A-C; Presentation time: Monday, November 14, 2011, 9:00am -10:00 am ET.
About C-21191 for Spasticity and Neuropathic Pain
C-21191 is a deuterium-modified subtype-selective GABAA modulator that represents a potential new therapeutic modality for the treatment of spasticity and chronic neuropathic pain. These conditions are associated with multiple neurological disorders including multiple sclerosis, stroke, spinal cord injury and cerebral palsy. Subtype-selective GABAA modulators have the potential to retain the known beneficial actions of the benzodiazepines—including spasmolytic and anxiolytic activities – while minimizing sedative effects and dependency potential. Additionally, C-21191 has demonstrated strong efficacy in a preclinical model of neuropathic pain. Concert is conducting preclinical studies to support the potential advancement of C-21191 into clinical testing.
Concert Pharmaceuticals is a clinical stage biotechnology company focused on applying the company's DCE Platform™ (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Concert's approach leverages decades of pharmaceutical and clinical experience to reduce the time, risk and expense needed to create important new medicines. The Company has a broad research pipeline encompassing many therapeutic areas including antiviral disease, renal disease, and CNS disorders, among others. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit www.concertpharma.com.
Concert Pharmaceuticals, the CoNCERT logo and the DCE Platform are trademarks of Concert Pharmaceuticals, Inc.
Contact: Concert Pharmaceuticals, Inc.
Justine E. Koenigsberg, 781-674-5284
The Yates Network
Kathryn Morris, 845-635-9828
Posted: October 2011